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Abstract
Ras proteins play a direct causal role in human cancer with activating mutations in Ras occurring in ∼30% of tumours. Ras effectors also
contribute to cancer, as mutations occur in Ras effectors, notably B-Raf and PI3-K, and drugs blocking elements of these pathways are in clinical
development. In 2000, a new Ras effector was identified, RAS-association domain family 1 (RASSF1), and expression of the RASSF1A isoform of
this gene is silenced in tumours by methylation of its promoter. Since methylation is reversible and demethylating agents are currently being used
in clinical trials, detection of RASSF1A silencing by promoter hypermethylation has potential clinical uses in cancer diagnosis, prognosis and
treatment. RASSF1A belongs to a new family of RAS effectors, of which there are currently 8 members (RASSF1–8). RASSF1–6 each contain a
variable N-terminal segment followed by a Ras-association (RA) domain of the Ral-GDS/AF6 type, and a specialised coiled-coil structure known
as a SARAH domain extending to the C-terminus. RASSF7–8 contain an N-terminal RA domain and a variable C-terminus. Members of the
RASSF family are thought to function as tumour suppressors by regulating the cell cycle and apoptosis. This review will summarise our current
knowledge of each member of the RASSF family and in particular what role they play in tumourigenesis, with a special focus on RASSF1A,
whose promoter methylation is one of the most frequent alterations found in human tumours.
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1.1. Introduction to Ras and its effectors
The Ras GTPases are a superfamily of molecular switches
that regulate a diverse range of functions, including cell
proliferation, differentiation, motility and apoptosis in response
to extracellular signals. The Ras proteins exist in two states: a
GTP-bound active state and a GDP-bound inactive state. In its
GTP-bound state, Ras is able to interact with its downstream
effectors, and mediate some component of Ras’ cellular actionsthrough complex signal transduction cascades (Fig. 1). Ras
effectors are proteins that specifically bind the GTP-bound form
of Ras via the Ras protein effector domain. Two of the best-
studied Ras effectors are Raf, a serine-threonine kinase that
controls the MEK-ERK pathway that activates cellular
proliferation [1], and phosphatidylinositol 3-kinase (PI3-K),
whose activity is required for activation of the protein kinase B,
Akt, which inhibits apoptosis induced by members of the Bcl-
family (such as BAD) [2]; see Fig. 1. Raf and PI3-K interact
with Ras through their Ras-binding domains (termed RBD and
PI3K_rbd, respectively). There is another group of Ras effectors
Fig. 1. Ras signalling pathways. Ras transmits signals from receptor tyrosine
kinases (RTK) to the nucleus and regulate a diverse array of biological functions.
Ras functions as a molecular switch, being inactive when bound to GDP and
active when bound to GTP. Activated Ras acts by regulating the cellular
response through distinct Ras effectors proteins and their complex signal
transduction cascades, such as mediated by the Raf serine/threonine kinases, the
lipid kinase, phosphatidylinositol 3-kinase (PI3-K) and the Ras association
domain family 1, RASSF1A. The best-characterised signal transduction
pathway of Ras is by the Raf kinases. Activated Raf phosphorylates MAPK/
ERK kinase (MEK) and the activated MEK phosphorylates the mitogen-
activated protein kinase (MAPK), which becomes activated and translocates to
the nucleus where it phosphorylates a set of transcription factors. For example,
the activation of Elk-1 leads to the transcription of Fos, which together with the
MAPK-activated Jun, forms the activation protein 1 (AP-1), which has been
shown to induce cyclin D1 and therefore stimulate proliferation. Another
cascade of Ras-activated signalling is by anti-apoptotic PI3-K, which can
stimulate the activity of the protein kinase B, Akt. Akt subsequently
phosphorylates BAD, a pro-apoptotic member of the Bcl-family, and thus
inhibits apoptosis (inactivating BAD enables BCL to promote cell survival by
blocking the release of mitochondrial cytochrome c and therefore inhibiting
caspase activation). Additionally, Ras regulates a pro-apoptotic pathway by
binding to the Ras effectors NORE1 and RASSF1A and RASSF1A can also
block cell cycle progression.
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Ras association (RA) domain, as defined by sequence
homologies between the Ras effectors, Ral guanosine nucleo-
tide-exchange factor (RalGDS; involved in Ras-induced
transformation) and the ALL-1 fusion partner from chromo-
some 6 (AF6; involved in regulating cell adhesion) [3,4].Recently, new genes encoding the RA domain have been
identified, and termed the Ras-association domain family
(RASSF), consisting of 8 members to-date, namely RASSF1
(123F2), RASSF2 (Rasfadin/KIAA0168), RASSF3, RASSF4
(AD037), RASSF5 (NORE1), RASSF6, RASSF7 (HRC1) and
RASSF8 (Fig. 2). However, although they interact either
directly or indirectly with activated Ras, their role in mediating
its biological effects remains unclear. What is clear is that they
seem to modulate some of the growth inhibitory responses
mediated by Ras and may serve as tumour suppressor genes.
Thus, RASSF proteins are tumour suppressors, in contrast to
traditional Ras effectors such as Raf and PI3-K, which are
oncoproteins.
1.2. Identification of RASSF1
Loss of heterozygosity (LOH) studies in lung, breast, and
kidney tumours identified several loci on chromosome 3p
(namely 3p12, 3p14, 3p21.3, and 3p25–26) that were likely to
harbour one or more tumour suppressor genes (TSGs). An
important TSG was suspected to reside in 3p21.3 because
instability of this region is the earliest and most frequently
detected deficiency in lung cancer [5–11]. Overlapping
homozygous deletions in lung and breast tumour cell lines
reduced the critical region in 3p21.3 to 120 kb in which eight
genes resided, namely CACNA2D2, PL6, 101F6, NPRL2/G21,
ZMYND10/BLU, RASSF1/123F2, FUS1, and HYAL2 [8,12].
However, despite extensive genetic analysis in lung and breast
tumours, none of these candidate genes were frequently
mutated.
At the same time, RASSF1 was identified in a yeast two-
hybrid screen through its interaction with the human DNA
excision repair protein XPA [13]. The nucleotide sequence of
the 1.7-kb cDNA identified matched the sequences of human
cosmid clones LUCA12 and LUCA13 [14], located in the
minimum homozygous deletion region of 120 kb in 3p21.3 [8].
The C-terminus showed high sequence homology (55%
identity) with a known murine RAS effector protein (Nore1)
[15] and contained a Ras-association (RA) domain. Hence the
gene name was changed from 123F2 to Ras-association domain
family 1 (RASSF1) gene [13].
1.3. Gene and protein structure of RASSF1
The RASSF1 gene locus is located on chromosome 3p21.3
and consists of eight exons spanning ∼11 kb. From this, seven
different transcripts are generated (RASSF1A-G) through the
use of differential promoters and alternative splicing (Fig. 3)
[12,13,16]. RASSF1A and RASSF1C, ubiquitously expressed in
normal tissues, are the major isoforms and are transcribed from
two different CpG island promoters ∼3.5 kb apart. These
isoforms have four common C-terminal exons (exons 3–6)
which encode a RalGDS/AF6 or Ras-association (RA) domain
[3,4] and a Sav/RASSF/Hpo (SARAH) domain (Hippo (Hpo) is
the Drosophila homolog of Mst1/2 and together with Salvador
(Sav) and Warts (Wts) promotes proper exit from the cell cycle
and apoptosis during development) [17]. RA domains mediate
Fig. 2. Schematic representation of the protein domains of members of the RASSF family described in the literature. Putative DAG-binding (C1, green), Ras
association (RA, red) and Sav/RASSF/Hpo interaction (SARAH, blue) domains are shown, predicted using Prosite (release 20.9) [209]. The Genbank ID ‘accession’
number is listed for each protein.
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domains mediate protein–protein interactions crucial in the
pathways that induce cell cycle arrest and apoptosis (heterotypic
interactions in the case of Sav, RASSF and Hpo, and homotypic
interactions in the case of Mst1). Exon 3 also contains a putative
ataxia telagectasia mutant (ATM) kinase phosphorylation
consensus sequence motif (a peptide containing this sequence
is phosphorylated in vitro, suggesting that RASSF1, like p53,
may be a substrate for ATM [18]). The 1.9-kb RASSF1A
transcript initiates from a promoter located in the first CpG
island and transcription initiates with exon 1α followed by exon
2αβ; these exons contain a diacylglycerol/phorbol ester-
binding (DAG) domain, also known as the protein kinase C
conserved region (C1), which contains a central zinc finger
(zinc-binding domain) [19]. The 1.7-kb RASSF1C transcript
initiates from a promoter located the second CpG island and
transcription initiates with a single N-terminal exon (exon 2γ),the protein sequence of which has no significant similarity to
any known protein (Fig. 3).
RASSF1B (also known as the ‘minor’ form or transcript) has
the same exon 2αβ as RASSF1A but utilises a different 5′ exon
(exon 1β; Fig. 3). RASSF1B is expressed predominantly in
haematopoietic cells and the transcript only encodes the RA and
SARAH domains [13]. The remaining 4 isoforms (RASSF1D-G)
are all splice variants of RASSF1A [16]; the RASSF1D transcript
is expressed specifically in cardiac cells and encodes four
additional amino acids 5′ of exon 2αβ, the RASSF1E transcript
is expressed specifically in pancreatic cells and has an additional
four amino acids 3′ of exon 2αβ, the RASSF1F transcript skips
exon 2αβ and produces a truncated peptide of 92 amino acids
that terminates within the C1 region, and the RASSF1G
transcript skips exons 2αβ-3 and produces a truncated peptide
of 152 amino acids that terminates just 5′ of the RA domain (Fig.
3). The biological function of these additional transcripts is
Fig. 3. Map of the RASSF1 gene. Through alternative promoter usage and splicing of the exons, 7 transcripts have been reported to be produced from the RASSF1
locus. RASSF1A (Vega: BCM:RASSF1-001, OTTHUMT00000264806), RASSF1B (Vega: BCM:RASSF1-003, OTTHUMT00000264808; Ensembl: Q9NS23-3,
ENST00000362008), RASSF1C (Vega: BCM:RASSF1-005 and -006, OTTHUMT00000264808 and OTTHUMT00000264807; Ensembl: Q9NS23-4,
ENST00000327761), RASSF1D (Vega: BCM:RASSF1-002, OTTHUMT00000264810; Ensembl: RASF1_HUMAN, ENST00000357043), RASSF1E (Ensembl:
Q9NS23-5, ENST00000359365), RASSF1F (Ensembl: Q9NS23-6, ENST00000273611), and RASSF1G (Vega: BCM:RASSF1-004, OTTHUMT00000264809;
Ensembl: Q9NS23-7, ENST00000266020). The Vega program also predicts 3 additional transcripts, however, these have yet to be experimentally verified and have
not been shown (BCM:RASSF1-007, OTTHUMT00000264812, a 601-bp transcript that produces a 133-amino acid protein with no recognisable domains; BCM:
RASSF1-008, OTTHUMT00000264813, a 571-bp transcript that produces a 41-amino acid protein with no recognisable domains; and BCM:RASSF1-009,
OTTHUMT00000264814, a 488-bp transcript that produces a 158-amino acid protein containing a C1 domain). UTR regions are depicted by open boxes, exons by
black boxes, promoters by black arrows and CpG islands by grey bars (as predicted by Ensembl). The domain structure of the protein products are predicted using
Prosite: putative ATM kinase phosphorylation consensus sequence motif (orange), DAG-binding (C1) domain (green), Ras association (RA) domain (red), and Sav/
RASSF/Hpo (SARAH) interaction domain (blue) domains. Position of the extra 4 amino acids in RASSF1D and RASSF1E (black asterisk). Ensembl (release 45) [20],
Vega (release 24) [165], Prosite (release 20.9) [209].
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from the first CpG island (namely RASSF1A and RASSF1D-G),
are frequently missing in a variety of tumours as a result of
epigenetic inactivation of the RASSF1A promoter.
1.4. Orthologues of RASSF1
Orthologues of RASSF1 have been predicted by Ensembl
(http://www.ensembl.org/index.html) in a wide range of organ-
isms, including mammals (elephant, cow, monkey, dog,
armadillo, opossum, rabbit, rat, mouse), birds (chicken), fish
(zebrafish, fugu, medaka, tetraodon, stickleback), worms, flies
and sea squirts, although they do not all show multiple
transcripts [20]. RASSF1A orthologues are present in many
model organisms including Mus musculus (Rassf1; GenbankID:AF132851), Danio rerio (zgc:92505; Genbank ID:
BC081661), and Caenorhabditis elegans (T24F1.3a; Genbank
ID:NP_001022361), with each having a C1, RA and SARAH
domain. The C. elegans gene product T24F1.3 is a 615 protein
containing a unique N-terminal segment, a central C1 zinc
finger (aa 165–214), a putative RA domain (aa 396–495), and a
C-terminal extension of 65 amino acids relative to NORE and
RASSF1A. The C-terminal 300 amino acids of RASSF1A and
NORE are ∼40% identical (70% similar) in sequence to the
central segment of T24F1.3 (containing the C1 and RA
domains), suggesting that T24F1.3 is a common precursor to
these two mammalian proteins [21]. T24F1.3, like other
members of the RASSF family, can bind to the proapoptotic
protein mammalian sterile 20-like kinase-1 and -2 (MST1 and
MST2) through the SARAH domains of each partner [21].
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T24F1.3 resulted in “no obvious phenotype” [22,23]. No
mutants or targeted knockdowns have been generated for the
zebrafish orthologue zgc:92505, however, in situ hybridisation
profiles of gene expression in various anatomical regions
during the different stages of zebrafish development reveal
some stages showing an “expression pattern linked to cell
proliferation” (http://mirror.zfin.org/cgi-bin/webdriver%3FMI-
val%3Daa%1Emarkerview.apg&OID=ZDB-GENE-040912-
14). Mice specifically carrying targeted deletions of the
Rassf1a isoform of Rassf1 show an increased incidence of
both spontaneous and induced tumourigenesis [24,25], con-
sistent with the role of RASSF1A as a tumour suppressor gene.
In Drosophila melanogaster there is only one RASSF family
member, dRASSF, which is encoded by the CG4656 gene
(Genbank ID:AY051923). Like its vertebrate counterparts,
dRASSF bears a C-terminal RA and SARAH domain, and
although it has an N-terminal LIM domain, this domain shares
some similarities with C1 zinc fingers. dRASSF restricts Hpo
activity by competing with the scaffold protein Sav for binding
to Hpo [26]. In addition, dRASSF was also observed to pos-
sess a tumour-suppressor function [26].
1.5. Silencing of RASSF1 in cancer
1.5.1. RASSF1A promoter methylation
Silencing of genes by DNA methylation is a common
phenomenon occurring in human cancer cells [27]. It has been
reported that promoter methylation plays an essential role in loss
of function of certain tumour suppressor genes [28]. Loss of
RASSF1A expression is one of the most common events in
human cancers, with aberrant promoter methylation reported in
at least 37 tumour types, including and abdominal paragan-
glioma, bladder, brain (neuroblastoma, glioblastoma, medullo-
blastoma), breast, cervical, cholangiocarcinomas, colon,
oesophageal, gastric, head and neck, hepatocellular, Hodgkin’s
lymphoma, kidney, lung (small cell lung cancer (SCLC), non-
small cell lung cancer (NSCLC), malignant mesothelioma),
melanoma, nasopharyngeal, osteosarcoma, ovarian, pancreatic,
prostate, pheochromocytoma, soft tissue sarcoma (including
leiomyosarcoma), testicular germ cell, thyroid and childhood
tumours (adrenocortical carcinoma, hepatoblastoma, leukaemia,
lymphoma, medulloblastoma, neuroblastoma, pancreatoblas-
toma, retinoblastoma, rhabdomyosarcoma and Wilms’ tumour)
[comprehensively listed in 29,30]. In general, RASSF1A
methylation frequency is higher in cancer cell lines compared
to the primary tumours, possibly due to the de novo methylation
that occurs when cells are kept in culture [31,32], however,
treatment with the DNA hypomethylating agent 5-aza-2′-
deoxycytidine reactivates the expression of RASSF1A. More
recently, hypermethylation of the RASSF1A promoter methyla-
tion was also found in human placentas (but not other foetal
tissues) during pregnancy (extending the analogy between the
primate placenta and malignant tumours to the epigenetic level)
[33].
Indeed, RASSF1A, promoter methylation has been demon-
strated in epithelial hyperplasia and intraductal papillomas ofthe breast, as well as cancerous epithelium [34] suggesting that
RASSF1A methylation is an early event in breast tumourigen-
esis. RASSF1A methylation has also been suggested to be an
early event in thyroid tumourigenesis [35], childhood neoplasia
[37] and endometrial carcinogenesis [38].
1.5.2. RASSF1A mutations
Loss of RASSF1A expression is largely attributed to
promoter hypermethylation, as somatic mutations of
RASSF1A are uncommon, although several polymorphisms
have been detected. In more than 200 samples lung, breast,
kidney and nasopharyngeal carcinomas and cell lines analysed,
only one frame-shift mutation (at codon 277 in the RA domain)
and one missense mutation (at codon 201 in the RA domain)
have been identified [13,16,39–41]. However, numerous
polymorphisms have been identified in these tumours and
cell lines, (NCBI dbSNP build 127 has 43 entries for
polymorphisms in RASSF1A [http://www.ncbi.nlm.nih.gov/
projects/SNP/]), many of which are located in the functional
domains of RASSF1A (five in the C1 domain, four in the ATM
phosphorylation site consensus sequence, and five in the RA
domain [detailed in 42]), and many of them have proven to
encode a functionally impaired mutant RASSF1A. For
example, A133S or S131F RASSF1A mutants cannot induce
cell cycle arrest by blocking cyclin D1 accumulation (the
S131F mutant also shows reduced phosphorylation resulting in
less efficient inhibition of cell proliferation) [43], C65R and
V211A mutants show reduced growth suppression activity both
in vitro and in vivo [44,45], and C65R and R257Q mutants
show reduced association with the microtubules [46]. Never-
theless, the functional significance of these alterations in
tumourigenesis remains to be determined. For example, one
study found frequent alterations at codon 133 in the
microtubule association and stabilization domain are preferen-
tially detected in patients with breast carcinoma and fibroade-
noma (a benign mammary tumour) compared to control patients
with non-tumourous alterations of the breast [47].
1.5.3. Loss of expression of other RASSF1 isoforms
Expression of the RASSF1B isoform was found to be lost in
two of four lymphoid tumour cell lines and seven of eight
bladder cancer cell lines [13,48]. However, loss of RASSF1B
expression was always concomitant with loss of RASSF1A
expression and expression of both was recovered following
treatment with a demethylating agent [48]. Thus, there have
been no reports of samples showing exclusive down-regulation
RASSF1B. RASSF1C did not show hypermethylation of its
promoter region and was expressed in almost all lung, breast
and paediatric tumours and tumour cell lines tested [13,16,49].
However, six of nine transformed ovarian cell lines have been
reported to have lost the expression of RASSF1C [50] and
RASSF1C expression was almost undetectable in the KRC/Y
renal cell carcinoma cell line [40]. Thus RASSF1C may have a
tissue-specific effect. Expression of RASSF1F is intimately
connected with RASSF1A expression because they share a
common promoter region [16,51]. Not surprisingly therefore,
re-expression of RASSF1A in 5-aza-2′ deoxycytidine-treated
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Although not reported, expression of RASSF1D, RASSF1E, and
RASSF1G is also likely to be linked with expression of
RASSF1A as they too share the same promoter region.
1.6. The use of RASSF1A methylation as a tumour biomarker
RASSF1A methylation has the potential to be an ideal cancer
biomarker as it occurs at moderate to high frequency in a very
wide range of tumour types, yet is comparatively rarely found in
normal tissues [34–36]. Thus, methylation of RASSF1A is
being considered for use in the clinic as a diagnostic marker, for
early tumour detection, and a prognostic marker, to predict the
risk of cancer development from benign growths, to predict the
prognosis of the patients with a diagnosed tumour, or even as a
marker for resistance to some treatments.
1.6.1. Diagnostic marker
It has been demonstrated that cancer patients have increased
levels of free DNA in their sera which has been released from
the cancer cells [52,53]. Silencing of tumour suppressor genes
has established promoter hypermethylation as a common
mechanism for tumour suppressor inactivation in human
cancers and thus is a promising new target for molecular
detection in bodily fluids. Methylation-specific PCR (MSP) can
determine the presence or absence of methylation of a gene
locus at a sensitivity level of up to 1 methylated allele in 1000
unmethylated alleles, appropriate for the detection of neoplastic
cells in a background of normal cells [54]. MSP also allows
rapid analysis of multiple gene loci, does not require prior
knowledge of epigenetic alteration, and can provide a “yes or
no” diagnostic answer.
The value of RASSF1A methylation as a diagnostic marker
has been investigated most thoroughly in lung cancer. For
example, RASSF1A methylation was found to occur in ∼34%
of NSCLC tumours, with concomitant methylation observed in
the corresponding serum [55,56]. RASSF1A methylation has
also been detected in the tumour and corresponding bronch-
oalveolar lavages in 29% (5/17) of methylated lung cancer cases
and when analysed in combination with 5 other tumour-related
genes, could diagnose lung cancer in 68% (21/31) of patients
[57]. RASSF1A methylation has also been found in the upper
aerodigestive tract, bronchial aspirates, plasma and sputum in a
significant proportion of current and former smokers [58–61],
which correlated with the number of pack years smoked during
the lifetime [59]. In general, DNA hypermethylation analysis
would be best used as a diagnostic marker in conjunction with
conventional diagnostic methods such as cytology and
histology. For example, analysis of RASSF1A, p16INK4A and
APC methylation in bronchial aspirates showed that cytology,
quantitative MSP and histology could detect lung cancer in
44%, 53% and 59% of cases respectively, yet when combined
diagnostic sensitivity extended to 81% (69/85) of patients [59].
RASSF1A methylation could also be a useful diagnostic
marker for other tumour types, such as breast, bladder and
kidney cancer. For example, methylation analysis of RASSF1A,
APC and DAPK1 was sufficient to differentiate normal fromtumour tissue in 94% of breast cancer cases and 76% of
corresponding serum DNA was also positive for methylation
[62]. Promoter methylation of APC, RARß2, and RASSF1A in
benign breast epithelium is associated with epidemiologic
markers of increased breast cancer risk (promoter methylation
of RASSF1A and APC occurred more frequently in unaffected
women at high-risk for breast cancer, as defined by the Gail
model, than in low/intermediate risk women) [63]. RASSF1A,
promoter methylation has been demonstrated in epithelial
hyperplasia and intraductal papillomas of the breast, as well as
cancerous epithelium [34] suggesting that RASSF1A methyla-
tion is an early event in breast tumourigenesis. Indeed,
RASSF1A methylation has also been suggested to be an early
event in thyroid tumourigenesis [35], childhood neoplasia [37]
and endometrial carcinogenesis [38].
In breast cancer patients where RASSF1A methylation may
be undetectable in the plasma, methylation has been shown to
be detectable in tumour DNA eluted from the surface of
erythrocytes and leukocytes [64] and in nipple aspirate fluid
[65]. Similarly, analysis of urine DNA represents a simple
method for kidney and bladder cancer detection. Several studies
have reported RASSF1A promoter methylation in urine DNA
from patients with kidney tumours, bladder cancer and
urothelial cancer but not in normal control samples or patients
with cystitis [66–68], although others have found RASSF1A
promoter methylation in normal bladder tissues [69,70],
although the frequency and extent of methylation appeared to
increase with age and malignancy [70]. Thus although MSP has
the potential to enhance early detection of bladder cancer using
a non-invasive urine test, the lack of tumour specificity in some
cases suggests further investigation is required before this test is
introduced into clinical practice. Recently, the presence of
localized prostate cancer was found to be detectable using
quantitative MSP on urinary cells obtained following prostate
massage, with the four-gene combination of GSTP1, RASSF1A,
RARβ2, and APC best discriminating malignant from non-
malignant cases (with 86% sensitivity and 89% accuracy),
suggesting that these panel of four genes could stratify patients
into low and high risk of having prostate cancer and optimize
the need for repeat prostatic biopsies [71].
The diagnostic potential of RASSF1A methylation has also
been explored in other cancers. For example, in a study
involving ovarian cancer patients the use of 6 genes
(RASSF1A, BRCA1, APC, DAPK1, p14ARF and p16INK4A)
gave 100% diagnostic coverage with RASSF1A methylation
detected in 50% cases; importantly, patient serum or peritoneal
fluid was positive for methylation in 88% of the tumour cases
analysed, even when the CA-125 (serum marker) levels were
low, underscoring the importance of having a reliable tumour
marker when early detection is crucial to patient outcome [72].
In a study of DNA collected from tampons, hypermethylation
of 3 or more of 5 candidate genes, including RASSF1A, was a
significant indicator of endometrial cancer and those patients
without endometrial cancer that showed hypermethylation of 3
or more genes were shown to have cervical cancer, endometrial
polyps or fibroids [73]. RASSF1A methylation has also been
detected in gliomas and corresponding patient serum [55].
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cancer patients was identified as a surrogate marker for the
monitoring of response to adjuvant tamoxifen treatment, with
persistence of RASSF1A methylation post-surgery and through-
out treatment indicating resistance to tamoxifen and loss of
methylation indicating a response [74]. However, it is important
to note that some studies have shown limited success in the
detection of RASSF1A methylation in serum. For example,
methylation was detected in 65% (34/52) of Hodgkin’s
lymphoma tumours but in only 2/22 corresponding serum
[75]. Similarly, a study of nasopharyngeal cancer found that
RASSF1A methylation was detected in 67% (20/30) of tumour
samples, yet only 37% of mouth and throat rinses, 33% of
nasopharyngeal swabs and 3% of plasma samples [76]. Taken
together these studies show that RASSF1A methylation can be
detected in a range of body fluids from cancer patients, with a
sensitivity that compares favourably with conventional diag-
nostic methods (although care must be put into selecting the
correct body fluid). ThusRASSF1Amethylation has the potential
to be used as a marker for early detection and monitoring (along
with a panel of other tumour suppressor genes to ensure 100%
coverage) and offers an exciting new approach to cancer
diagnosis.
1.6.2. Prognostic marker
For some cancers an association between RASSF1Amethyla-
tion and adverse patient survival has been observed. In NSCLC
patients, some studies have found that RASSF1A methylation
correlates with poor survival rate and is associated with poorly
differentiated tumours, predominantly with vascular invasion
and pleural involvement [16,77,78] although others have found
no such correlation [79–81]. However, an association has been
observed between RASSF1Amethylation, age at which smoking
began and a decreased survival rate [82], and RASSF1A
methylation and earlier recurrence of lung cancer [51]. Thus
although it looks promising, further studies are needed to clarify
the prognostic value of RASSF1A methylation in lung cancer.
Methylation of RASSF1A, together with that of other tumour-
related genes, may be useful as a marker for tumour progression
and metastasis, as many studies have shown this occurs
significantly more frequently in tumours of a higher-grade,
later stage, more invasive or metastatic tumours, including
prostate cancer [83–86], breast cancer [87,88], bladder cancer
[48,70,89–92], endometrial cancer [93], neuroendocrine
tumours [94,95], melanoma [96], glioma [97], gastric adeno-
carcinoma [98], salivary adenoid cystic carcinoma [99], pituitary
adenoma [100], and malignant pleural effusions [101]. It has
recently been proposed that since the RASSF1A methylation
index showed a gradual increase from non-lesional liver to
regenerative/hyperplastic conditions (chronic liver disease and
focal nodular hyperplasia), to preneoplastic lesions to overt
tumours, quantitative analysis of RASSF1A gene promoter
methylation, rather than the detection of methylation bands per
se, might be clinically relevant [102]. It was also recently found
that hepatocellular carcinoma (HCC) associated with cirrhosis
showed significantly higher frequency of RASSF1A promoter
methylation than HCC without cirrhosis [103]. Yet it must benoted that not all studies have found positive correlates with
RASSF1A methylation and tumour grade/stage [37,104,105],
with some reporting RASSF1Amethylation in benign epithelium
as well as in the lesions associated with high risk of cancer
formation [106] (though it could be argued that this may be a
sign of clinically relevant but still benign hyperplasia [107]).
However, in general, RASSF1A methylation in tumour tissue
and corresponding body fluids often correlates with advanced
tumour stage and grade, metastasis, poor tumour differentiation
and adverse survival.
1.7. Correlation between RASSF1A methylation and other
oncogenic events
Due to the evidence linking RASSF1A to Ras signalling
pathways, several studies have looked for correlation between
mutation of K-Ras and inactivation of RASSF1A by methyla-
tion. An inverse correlation was observed in colorectal cancers
[108], pancreatic adenocarcinomas [109], and NSCLC [110].
However, other studies of NSCLC have found no correlation
between methylation of RASSF1A and activating mutations in
K-Ras [111,112]. Synergy between RASSF1A and members
of the Ras signalling pathway has been proposed in melanomas
where most tumours and all cell lines with RASSF1A promoter
methylation additionally carried B-Raf or N-Ras mutations
[113]. Interestingly, in thyroid cancer the situation appears to be
reversed as RASSF1A hypermethylation and B-Raf mutations
events were mutually exclusive [35]. There is no correlation in
the methylation status between RASGRF2 (a Ras guanine
nucleotide exchange factor capable of activating Ras) and
RASSF1A in NSCLC [114]. These differences between the
tissues may simply be a reflection of alterations occurring in
other Ras signalling pathways.
Other genes have been reported to show concomitant
inactivation with RASSF1A silencing. For example, 90% of
undifferentiated thyroid carcinomas examined with p16INK4A
inactivation were also silenced for RASSF1A expression [115]
and RASSF1A and p16INK4A methylation in stage IIIA lung
adenocarcinomas have been shown to be profound indicators of
poor survival [78]. A statistically significant association
between hypermethylation of RASSF1A and hypermethylation
of CASP8 was found in neuroblastic tumours [116]. In
hepatocellular carcinoma, a significant association between
‘CpG island methylator phenotype’ (CIMP; in which multiple
genes are concurrently methylated in tumours) and methylation
of RASSF1A has been reported [117]. However, the significance
of these findings, in terms of synergy between these genes and
their signalling pathways in tumour formation needs to be
further investigated.
Some cancers are associated with infection of the tumour
cells by oncogenic viruses, such as human papillomavirus
(HPV), human herpes virus (EBV), and simian virus 40 (SV40).
For example, cervical cancer and head and neck squamous cell
carcinoma (HNSCC) are associated with HPV infection of the
tumour cells (the HPV encodes viral proteins (E6 and E7) to
subvert control of the cell cycle by inactivating p53 and Rb,
respectively). Interestingly, HPV DNA was never found in
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RASSF1A [118,119], suggesting that the presence of viral
proteins abrogated any requirement for RASSF1A inactivation
and thus implicating them both in the same pathway. However,
no inverse correlation between RASSF1A methylation and HPV
infection was found in cervical cancers [120,121]. The EBV is
associated with a number of neoplasias, including nasophar-
yngeal carcinoma, Hodgkin’s lymphoma, and gastric carcino-
mas. Although RASSF1A methylation is detected in the
majority of nasopharyngeal carcinomas [comprehensively
reviewed in 29], it is difficult to draw any correlations regarding
viral infection of the tumour cells because virtually all cases are
EBV positive. However, comparisons between EBV infection
and RASSF1A methylation are possible with Hodgkin’s
lymphoma and gastric carcinomas as only a subset are EBV
positive and although RASSF1A methylation did not correlate
with EBV infection in a study of Hodgkin’s lymphoma cases
[75], a correlation between EBV infection and RASSF1A
methylation was detected in gastric carcinoma [122]. Finally,
malignant mesothelioma is frequently associated with SV40
infection, and RASSF1A methylation has been shown to be
significantly higher in SV40-positive malignant mesotheliomas
than SV40-negative cases [123,124]. Interestingly, a correlation
was found in hepatocellular carcinoma tumours between the
methylation status of RASSF1A and the presence of DNA
damage resulting from aflatoxin B1 (an environmental carcino-
gen that causes DNA adducts) [125].
1.8. Understanding the mechanism of action for RASSF1’s
tumour suppressor function
RASSF1A has been found to be inactivated in more than 40
types of sporadic human cancers, suggesting it plays a key role
in tumour prevention. Consistent with this, constitutive over-
expression of RASSF1A in various tumour cell lines (NSCLC,
prostate, kidney, nasopharyngeal carcinoma, and glioma cell
lines) results in cells that are less viable, growth suppressed, less
invasive, and show reduced anchorage/substrate independence
[13,16,40,44,97,126]. Over-expression or ectopic expression of
RASSF1A in lung, kidney, nasopharyngeal and prostate cancer
cell lines causes drastic reduction of tumourigenicity both in
vitro and in vivo, whereas expression of mutant forms of
RASSF1A only showed reduced growth suppression activity
[13,16,40,44,45,126,127].
In contrast to RASSF1A, a role for RASSF1C in tumour
suppression is not clear as reports of its activities are mixed. For
example, ectopic expression of RASSF1C showed no significant
effects on growth and induction of apoptosis in the H1299 and
A549 cells NSCLC cell lines in vitro and in vivo [127], no
suppression of anchorage-independent growth in the H1299 cell
line in vitro [16] and no growth inhibitory activity of the U2020
SCLC cell line in vitro [45]. Vos and co-workers found that the
growth inhibitory effects of RASSF1C in 293T cells were
dependent upon the presence of activated RasG12V [50].
However, over-expression of RASSF1C activated osteoblast
cell proliferation (through interaction with IGFBP-5) [128] and
a reduction in RASSF1C expression caused decreased lungcancer cell proliferation [129]. In contrast, both RASSF1A and
RASSF1C showed similar growth inhibitory activities of the
prostate cell line LNCaP and renal cell carcinoma line KRC/Y
in vitro, and suppression of tumourigenicity of the KRC/Y cell
line in vivo [45]. Mutations in both RASSF1A and RASSF1C
were also detected in a gene inactivation test in vivo [45]. More
recently, RASSF1A and RASSF1C isoforms have been shown
to have opposite effects in controlling the degradation of β-
catenin (via regulation of the SCFßTrCP ubiquitin ligase); β-
catenin accumulation is promoted by over-expression of
RASSF1C or silencing of RASSF1A [130]. This suggests that
inhibition of ß-catenin accumulation could be one of the
mechanisms by which RASSF1A exerts its tumour suppressor
function, and RASSF1C expression in the absence of
RASSF1A could play a role in tumourigenesis [130]. Thus
additional investigations will be needed to better understand the
role of RASSF1C in tumourigenesis, in particular, is it restricted
to certain tumour types and are its effects dependent upon it
being present in greater amounts than RASSF1A (such as would
occur with selective methylation of the RASSF1A promoter in
tumourigenesis)?
Mouse models of human cancer have greatly advanced our
understanding of tumourigenesis. The first mice lacking Rassf1
were made by Smith and colleagues, who used chromosomal
engineering to generate mice carrying a 370-kb deletion
(encompassing 12 genes including Rassf1) of the region
syntenic to the minimal deletion region on human 3p21.3,
frequently deleted in lung tumours [131]. Although homo-
zygous null mice were embryonic lethal, heterozygous mice
were viable and fertile, despite being haploinsufficient for 12
genes, and it remains to be seen whether these mice show an
increased incidence of tumourigenesis [131]. The generation of
knockout mice deficient for only the Rassf1a isoform of Rassf1
[24,25] mimics the situation seen in human tumours in which
RASSF1A, but not RASSF1C, is missing. Rassf1a null mice
showed an increased incidence of spontaneous tumourigenesis
(predominantly lymphomas) and decreased survival rate
compared with wild-type mice [24,25]. Rassf1a null mice
exposed to physical (irradiation) and chemical (benzo[a]pyrene
and urethane) mutagens also showed increased tumour
susceptibility relative to controls [24,25]. These data are
consistent with the role of a tumour suppressor gene, and
suggest that RASSF1A inactivation in combination with other
genetic or epigenetic alterations may produce a more severe
tumour susceptibility phenotype. However, the mechanisms by
which RASSF1A exerts its tumour suppression activities or the
pathways it can regulate are not yet fully understood. RASSF1A
has been reported to play a role in diverse activities including
the regulation of apoptosis and genomic instability as well
regulating microtubule dynamics during the cell cycle/mitotic
progression, and thus may serve as a node in the integration of
signalling pathways controlling a range of critical cellular
functions (summarised in Fig. 4).
1.8.1. Microtubule and centrosome binding activities
RASSF1A co-localizes with microtubules in interphase and
decorates spindles and centrosomes during mitosis (RASSF1A
Fig. 4. A summary of the reported RASSF1A interactions and RASSF1A-mediated biological functions. RASSF1A can regulate the microtubule network, cell cycle
progression and apoptosis by recruiting effectors and their signalling pathways. Proteins that directly interact (bind) with RASSF1A are shown in green, with
downstream proteins affected by this interaction shown in blue. RASSF1A induces apoptosis through its interaction with Ras, the Ras effector NORE1, the connector
enhancer of KSR (CNK1), the pro-apoptotic kinase MST1, and the modulator of apoptosis-1 (MAP-1; activated K-Ras, RASSF1A, and MAP-1 synergize to induce
Bax activation and cell death). RASSF1A regulates proliferation through its interactions with the microtubules and Cdc20 (by inhibiting the APC–Cdc20 complex and
its degradation of cyclins A and B), the microtubule-associated protein 1B (MAP1B), Aurora-A (which phosphorylates RASSF1A), C19ORF5 (the C19ORF5–
RASSF1A interaction at the centrosome is thought to be required for the proper control of the APC–Cdc20 complex during mitosis), the transcription factor p120E4F
(RASSF1A-induced G1 cell cycle arrest and S-phase inhibition was enhanced by p120E4F) and inhibition of cyclin D1 accumulation. RASSF1A also inhibits the
epidermal growth factor-dependent activation of Erk through the plasma membrane calmodulin-dependent calcium ATPase 4b (PMCA4b). Taken together, these
activities all support a tumour suppressor role for RASSF1A.
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during prophase, then to the spindle fibres and poles during
metaphase and anaphase and finally to the midbody during
cytokinesis) [132,133]. Deletion analysis identified the region
between amino acids 120 and 185 as the microtubule associa-
tion domain [134]. Re-expression of RASSF1A in RASSF1A-
negative cell lines induces microtubule stabilisation and
protects the cells from the actions of microtubule depolymeris-
ing agents, such as nocodazole [46,132,134,135]. Two naturally
occurring missense mutations in RASSF1A, C65R and R257Q,
resulted in RASSF1A mutants that were deficient in their ability
to bind microtubules, were less competent at induction of
microtubule acetylation and failed to protect against nocoda-
zole-induced polymerisation [46]. These mutants were also
deficient in their ability to stop DNA synthesis in NCI-H1299cells [46], suggesting a link between competency to bind
microtubules and ability to induce cell cycle arrest.
A yeast two-hybrid screen to identify novel RASSF1A-
interacting proteins found 70% of interacting clones had
homology to microtubule-associated proteins, including
MAP1B and C19ORF5, suggesting that RASSF1A may exert
its tumour-suppressive functions through interaction with the
microtubules [46]. The interaction of C19ORF5 (also known as
BPY2IP1 or MAP1S) and RASSF1A was independently
confirmed by other groups [133,136]. C19ORF5 is a ubiqui-
tously expressed member of the MAP1A/B family of micro-
tubule-associated proteins and accumulation of c19ORF5
causes mitochondrial aggregation and cell death [136]. The
C19ORF5–RASSF1A interaction at the centrosome is thought
to be required for the proper control of the anaphase-promoting
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also interact with LRPPRC; C19ORF5 and LRPPRC colocalize
with β-tubulin in the cytoplasm, however, in apoptotic cells,
they are found to colocalize in the nucleus [136]. An interaction
between C19ORF5 and the mitochondrial proteins (NADH-
dehydrogenase subunit 1 and cyclooxygenase-1) and LRPPRC
associates RASSF1 with mitochondria, an organelle with
pivotal functioning in control of apoptosis [136]. Furthermore,
depletion of C19ORF5 causes mitotic abnormalities [137]. Thus
when taken together with the fact that other microtubule-
binding and stabilising proteins are known to also possess
tumour suppressor activities (including adenomatous polyposis
coli and von Hippel–Lindau proteins), the association of
RASSF1A with the microtubules is likely to play an important
role in its tumour suppressor activity.
The microtubular association and effect of RASSF1C on
stabilization has been reported to be undetectable [133],
weaker than [134], or equal to RASSF1A [135], depending
on the cell line used. Indeed, Liu and colleagues showed that
when expressed alone, RASSF1A and RASSF1C isoforms
exhibit identical cellular locations, paclitaxel-like hyperstabil-
ization of microtubules, and paclitaxel-like interference with
mitosis [138]. However, when co-expressed with C19ORF5,
RASSF1C failed to associate with and promote hyperstabil-
ization of microtubules and it was specifically RASSF1A
that caused microtubule hyperstabilization and the accumula-
tion of C19ORF5 on them [138]. This could be the unique
property that underpins tumour suppression by only the
RASSF1A, not RASSF1C isoform, thus underlying the
specific effect of hypermethylation-suppressed RASSF1A in
tumour suppression.
1.8.2. Regulating the cell cycle and mitotic progression
Deregulation of the cell cycle is an essential requirement for
tumourigenesis. In normal cells, cycling is tightly controlled by
a number of protein complexes whose activity is required for the
cell to pass through specific checkpoints. RASSF1A has been
shown to induce cell cycle arrest by engaging the Rb family cell
cycle checkpoint which regulates entry into S phase. Reintro-
duction of RASSF1A expression in lung and breast cancer cell
lines (NCI-H1299 and HME50-hTERT, respectively) results in
growth arrest and an inhibition of cyclin D1 protein accumula-
tion (through inhibition of mRNA translation), which can be
relieved by ectopic expression of cyclin D1 or other down-
stream activators of the G1/S-phase transition (such as cyclin A
and E7) [43]. Concomitantly, down-regulation of endogenous
RASSF1A expression in human epithelial cells resulted in
abnormal accumulation of cyclin D1 protein in the absence of
detectable changes in cyclin D1 mRNA levels [43]. Consistent
with this study, re-expression of RASSF1A in a NSCLC cell line
(A549) induced G1 cell cycle arrest and these cells showed a
down-regulation of cyclins D1 and D3 [139]. Similarly, over-
expression of RASSF1A in the MCF-7 breast cancer cell line
exhibited a G1 arrest [135] (although others found no cell cycle
arrest [140]). However, the RASSF1A-induced G1 arrest was
found to be transient (24–48 hours following transfection) and
RASSF1A over-expression also induced a G2/M arrest in thesecells (72 hours following transfection) [135]. Interestingly,
RASSF1A did not induce G1 arrest in 293T cells (a human
embryonic kidney cell line), but rather a more pronounced G2/M
arrest was noted [133,135].
In a yeast two-hybrid screen, p120E4F was identified as an
interaction partner of RASSF1A (via amino acids 1 to 119 of
RASSF1A) [141]. p120E4F is an E1A-regulated transcription
factor which interacts with the tumour suppressor genes
p14ARF, Rb and p53 and is involved in control of cell cycle
arrest near the G1 transition. RASSF1A-induced G1 cell cycle
arrest and S-phase inhibition was enhanced by p120E4F [141].
Furthermore, knockdown of endogenous RASSF1A in the
breast tumour cell line HB2 and the cervical cancer cell line
HeLa leads to a reduction in the binding capacity of p120E4F to
the cyclin A2 promoter, whereas the binding capacity is
increased in an A549 lung cancer cell line stably expressing
RASSF1A [142]. This suggests that cyclin A2, which regulates
CDK2 and thereby controls progression through S phase, is the
cellular target for RASSF1A through p120E4F, and proposes a
transcriptional mechanism for RASSF1A-dependent cell cycle
regulation. It has also been proposed that RASSF1A blocks
cell cycle arrest at the G1 phase through the c-Jun-NH2-kinase
(JNK) pathway, as H1299 lung cancer cells stably transfected
with RASSF1A showed reduced JNK and c-Jun phosphoryla-
tion, inhibition of JNK activity and down-regulation of cyclin
D1 [143].
Over-expression of RASSF1A in 293T and HeLa cells
induced stabilization of mitotic cyclins (cyclins A and B) and
a mitotic arrest at prometaphase [133]. RASSF1A was also
shown to interact with Cdc20, an activator of the anaphase-
promoting complex (APC; a protein complex that interacts with
ubiquitin-conjugating and activating enzymes to catalyze the
ubiquitylation of proteins destined for degradation to allow the
cell cycle to progress). After interaction with RASSF1A, Cdc20
is inhibited to activate APC and therefore APC is unable to
degrade the mitotic cyclins A and B [133]. Conversely, RNAi-
mediated inactivation of RASSF1A in HeLA cells resulted in
acceleration of mitotic progression and the premature destruc-
tion of cyclins A and B [133]. The RASSF1A-mediated
regulation of Cdc20 during mitosis also appeared to be
independent of Mad2 and Emi1 (potent negative regulators of
Cdc20 during mitotic progression), implying that RASSF1A
acts in early prometaphase (after Emi1 destruction and before
activation of theMad2-dependent spindle checkpoint) to prevent
the degradation of mitotic cyclins and to delay mitotic
progression beyond metaphase (APC is inhibited by sequestra-
tion of Cdc20 by Emi1 during S, G2, and prophase, then during
prometaphase, RASSF1A takes on the role of the Cdc20
regulator) [133,144]. RASSF1A’s inhibition of APC–Cdc20
activity during mitosis was subsequently shown to be regulated
by RASSF1A-binding protein 1 (RBP1; previously termed
C19ORF5), as RNAi-mediated depletion of RBP1 prevented
both the localization of RASSF1A to the spindle poles and it’s
binding to Cdc20, resulting in premature destruction of mitotic
cyclins and acceleration of mitotic progression [145]. Thus
RASSF1A may mediate its tumour suppressive effects by
inducing growth arrest in the G1 and G2/M phases and regulating
69L. van der Weyden, D.J. Adams / Biochimica et Biophysica Acta 1776 (2007) 58–85mitotic progression via regulation of the APC complex and
accumulation of cyclins A, B and D1 [133,144,146,147].
However, Rassf1a null mouse embryonic fibroblasts
(Rassf1a+/+ MEFs) were recently shown to display evidence
of delayed mitosis (taking a longer time to traverse mitosis than
Rassf1a+/+MEFs, with some of them failing to complete mitosis
as a result of cytokinesis failure) [148]. Furthermore, this defect
was complemented, at least partially, by expression of either
RASSF1A or components of the mammalian Hippo pathway,
namely MST2, WW45 and LATS1 (recent work in Drosophila
has identified a new tumour-suppressor pathway involving the
Drosophila MST1 and MST2 ortholog, Hpo, as well as Lats/
Warts serine/threonine kinase (LATS1) and Sav, of which
WW45 is the human ortholog; RASSF1A, MST1, MST2 and
Sav all contain a conserved C-terminal SARAH domain,
required for protein–protein interactions) [148]. Furthermore,
RASSF1A is a microtubule-binding and stabilising protein (see
previous section) and disruption of microtubule dynamics either
by microtubule-stabilizing/destabilizing agents or proteins
affects cell cycle progression at M phase [reviewed in
149,150]. Indeed, RASSF1A has been shown to interact with
the microtubule-associated protein C19ORF5/MAP1S, and
siRNA-mediated knockdownC19ORF5 causes mitotic abnorm-
alities and disrupts the microtubule-organizing centre [137]. In
addition, Aurora-A interacts with and phosphorylates
RASSF1A (residues Thr202 and/or Ser203 located in the
microtubule-binding domain), and substitutions of these re-
sidues with glutamic acid at both positions, which mimicks
constitutive phosphorylation of RASSF1A, disrupt its interac-
tions with microtubules and abolish its ability to induceM-phase
cell cycle arrest (Aurora-A overexpression also interferes with
RASSF1A-mediated growth suppression) [151]. Thus further
studies are needed to elucidate whether the primary cause of
RASSF1A-induced mitotic arrest occurs via altered microtubule
stabilization or via interactions with Cdc20 or members of the
Hippo pathway (or both).
RASSF1 has also been shown to interact with plasma mem-
brane calmodulin-dependent calcium ATPase 4b (PMCA4b)
[152]. In a two-hybrid screen, the catalytic domain of PMCA4b
was found to interact with RASSF1 (via amino acids 144–193 of
RASSF1A or amino acids 74–123 of RASSF1C), with co-
expression in cells causing inhibition of the epidermal growth
factor (EGF)-dependent activation of the Erk pathway (Erk is a
downstream target of the Ras-Raf-MEK signalling cascade that
activates cellular proliferation, see Fig. 1) [152].
A role for RASSF1C in cell cycle regulation has been
considerably less well-studied (over-expression of RASSF1C
induced cell cycle arrest in KRC/Y cells [45], yet over-
expression in HeLa cells showed no effect on the cell cycle
[133]) and thus remains unclear.
1.8.3. Controlling genomic stability
Given RASSF1A localizes to the mitotic spindle and can
complex with the centrosome component γ-tubulin (see Section
1.8.1), and defects in spindle regulation can lead to genomic
instability [153], RASSF1A has investigated for its ability to
influence genomic stability. Expression of activated Ras hasbeen associated with genomic instability, giving rise to
polyploidy, aneuploidy, and derangements of the nuclear
structure [134,154,155]. Over-expression of RASSF1A or
RASSF1C in the human embryonic kidney cell line 293T or
human lung tumour cell line NCI-H1299 blocked the ability of
activated Ras to induce genomic instability [134]. Interestingly,
a point mutant of RASSF1C, S61F, which was severely de-
fective for stabilizing tubulin, was unable to block the genomic
destabilizing effects of Ras (the S61F mutant is equivalent to the
S131F mutation of RASSF1A, and these mutations abolish the
ATM phosphorylation site in both isoforms) [134]. A
substantial proportion of human foreskin fibroblasts depleted
of RASSF1A by infection with a retrovirus-based siRNA vector
contained more than two centrosomes and showed various
mitotic spindle abnormalities including the formation of
multipolar spindles, misalignment of chromosomes, and
lagging chromosomes, suggestive of chromosome instability
[133]. More recently, a significant proportion of cultured
fibroblasts from Rassf1a null mouse embryos (Rassf1a–/–
MEFs) were found to exhibit delayed mitosis which resulted
in cytokinesis failure [148]. However, in vivo analysis of
genomic instability by examination of the presence of
micronuclei in the blood showed no increase in the percentage
of micronuclei from Rassf1a–/– mice compared to wild-type
littermates (even in aged mice or mice exposed to DNA damage
by low-dose irradiation) [24]. Similarly, Rassf1a–/– MEFs from
these mice did not show a significant proportion of cells with
more than 2 centrosomes or any gross chromosomal rearrange-
ments by SKY analysis [24]. Thus further detailed analysis will
be required to determine whether RASSF1A (or RASSF1C) has
a role to play in regulating genomic instability.
1.8.4. Involvement in the pro-apoptotic pathway
Activated Ras is usually associated with enhanced prolifera-
tion, transformation and cell survival (see Fig. 1). However Ras
can also induce proliferation inhibitory effects and apoptosis.
Ras effectors, such as RASSF1, may be specialised to inhibit
cell growth and induce cell death, such that inhibition of these
pathways, via methylation of the RASSF1A promoter, may be
necessary for tumourigenesis. An interaction between
RASSF1C and RasG12V was detected during transient
expression in mammalian cells by Vos and co-workers [50].
However, others found that neither RASSF1A or RASSF1C (or
the C. elegans homolog T24F1.3) showed any significant
ability to bind directly to RasG12Vor several related GTPases,
as determined quantitatively in a yeast two-hybrid assay, by co-
transfection in mammalian cells and by binding in vitro (the
difference in results was postulated to be because the former
study employed much higher amounts of RASSF1 cDNA and
higher ratios of RASSF1 to Ras DNA) [21,156]. Instead, it was
shown that RASSF1A, unlike RASSF1C, was able to both
homodimerise and form heterodimers with the Ras-GTP
binding protein, Nore1 (this dimerisation required the amino-
terminal 119 amino acids of RASSF1A which are not found in
the B and C isoforms) [156]. Thus the ability of RASSF1A to
heterodimerise with Nore1 confers an indirect association with
Ras-GTP in vivo.
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apoptosis to the tumour-suppressive actions of RASSF1. Over-
expression of RASSF1A in MCF-7 breast cancer cells resulted
in morphological and biochemical changes suggestive of
apoptosis (cell rounding, increased annexin V staining and
appearance of a sub-G1 population) [140] and transient
expression of RASSF1C in 293-T cells resulted in substantial
apoptosis, that was augmented by co-expression with mutant
active Ras [50]. In contrast, others have failed to detect any
apoptosis in 293-T cells over-expressing only wild-type
RASSF1A or RASSF1C [157]. Thus, the evidence that any
isoforms of RASSF1 can initiate apoptosis when over-
expressed singly is conflicting. However, there are several
lines of evidence to suggest that RASSF1A can participate in
pro-apoptotic pathways. For example, RASSF1, its homologue
NORE1 and C. elegans orthologue T24F1.3 have all been
shown in a yeast two-hybrid assay to specifically bind the pro-
apoptotic MST1 (the MST1 binding site is at the C-terminal
end of RASSF1A) [21]. MST becomes activated by auto-
phosphorylation of threonine (at position 183 of MST1 and 180
of MST2), however, this can be inhibited by co-transfection
with RASSF1A or RASSF1C (or NORE1) [158]. Over-
expression of mammalian MST1 or MST2 promotes apoptosis,
as does over-expression of mutant active Ki-Ras. NORE1A and
RASSF1A are constitutively complexed with MST1 and
interference with the ability of endogenous MST1/2 to
associate with these proteins inhibits Ras-induced apoptosis
[158,159]. Thus RASSF1A (and NORE1) may serve as sensory
modules to detect pro-apoptotic signals initiated through Ras
pathways [21,158]. The RASSF1A–MST1 complex may also
indirectly associate with Ras via the scaffold protein CNK1
[157]. CNK1 is a scaffold protein that in Drosophila is required
for Ras to activate Raf kinase, and transfection of CNK1 into
293 cells can induce apoptosis [157]. Since CNK1 can bind
RASSF1A or RASSF1C (but not NORE1) [157] and
RASSF1A can interact with MST1/2 [21], it was proposed
that RASSF1A may provide the mechanism linking the two
proteins. Indeed, deletion of the C-terminal (RASSF1-interact-
ing) region of MST1 prevented its interaction with CNK1 and
despite the fact that both RASSF1A and RASSF1C can interact
with CNK1, only RASSF1A is able to augment CNK-induced
apoptosis [157].
RASSF1A may also regulate apoptosis via the death receptor
signalling pathway. Activated death receptors evoke Bax
conformational change, cytochrome c release, and cell death,
and RASSF1A has been shown to be required for death
receptor-induced Bax conformational change and apoptosis
[140]. Stimulation of the death receptors with TNFα (tumour
necrosis factor α) or TNFα-related apoptosis-inducing ligand
(TRAIL) resulted in recruitment of RASSF1A and modulator of
apoptosis-1 (MAP-1) proteins to the receptor complexes and
promoted complex formation between RASSF1A and MAP-1;
MAP-1 is normally inhibited by an intramolecular interaction,
however, the binding of RASSF1A to MAP-1 relieved this
inhibitory interaction, resulting in MAP-1 association with Bax
[140]. It was subsequently shown that activated K-Ras,
RASSF1A, and MAP-1 synergize to induce Bax activationand cell death, with shRNA-mediated inhibition of RASSF1A or
use of a tumour-derived point mutant of RASSF1A showing
impaired the ability of K-Ras to activate Bax [160].
The recent finding that RASSF1C is a binding partner of
Daxx could also allow RASSF1C to play a role in regulating
apoptosis. RASSF1C, constitutively anchored by Daxx in
promyelocytic leukaemia-nuclear bodies, is released from the
nucleus when Daxx is degraded following DNA damage,
translocates to the cytoplasmic microtubules and participates in
activation of stress-activated protein kinase/c-Jun N-terminal
kinase (SAPK/JNK) pathway, which responds to a variety of
stress stimuli and controls cell fates such as cell cycle entrance,
apoptosis and senescence [161].
1.8.5. Controlling cell migration/adhesion
The microtubule stability induced by RASSF1A could have
implications for cell adhesion and motility, especially in the
light of microarray data showing that genes for cell adhesion
and motility such as tropomyosin I and CDH2 were up-
regulated in A549 NSCLC cells stably expressing RASSF1A
[139]. Indeed, RASSF1A methylation in well-differentiated
neuroendocrine tumours (including pancreatic endocrine
tumours and carcinoid tumours) [98] and adenoid cystic
carcinoma of the salivary gland [103] have been found to be
more frequent in tumours showing metastasis. Recently, it was
shown that over-expression of RASSF1A diminished the
ability of A549 NSCLC cells to migrate either through a
transwell filter or to close a wound [162]. In addition, A549
cells stably transfected with RASSF1A exhibited increased
cell–cell adhesion, whereas Rassf1a null mouse embryonic
fibroblasts and RASSF1A-depleted HeLa cells showed loss of
cell–cell adhesion and an increased cell migration that could be
partly PI3-K dependent and was associated with increased
activation of Rac1 [162]. These findings represent a novel
function for RASSF1A, which may help explain its tumour
suppression ability independently of its effects on cell cycle and
apoptosis.
2. RASSF2
2.1. Gene and protein structure of RASSF2
Located on human chromosome 20p13, RASSF2, originally
called Rasfadin, was first identified as a novel gene close to the
bovine prion gene and shows a high nucleotide (88%) and amino
acid similarity (95%) with a previously described human cDNA,
KIAA0168 [163]. In silico characterisation of RASSF2 reported
three isoforms (RASSF2A, RASSF2B and RASSF2C), with only
the RASSF2A isoform having a 5′ CpG island and predicted
promoter region (the open reading frame of RASSF2A was
cloned from a brain-specific cDNA library) [164]. Consistent
with this, the Vega program [165] predicts 3 transcripts from the
RASSF2 locus, with only the RASSF2A transcript (termed
RASSF2-001) being translated (see Fig. 5). RASSF2A is a 326-
amino acid protein containing an RA domain and acidic coiled-
coil SARAH domain (see Fig. 2). RASSF2 lacks the cysteine-
rich domain of NORE1 and RASSF1A, however, the RA
Fig. 5. Transcripts produced from the RASSF2 locus at chromosome 20p13. Three transcripts are produced from the RASSF2 locus, namely RASSF2A (Vega:
RASSF2-001, OTTHUMT00000077828; Ensembl: RASF2_HUMAN, ENST00000379400), RASSF2B (Vega: RASSF2-002, OTTHUMT00000077829), and
RASSF2C (Vega: RASSF2-003, OTTHUMT00000253005; Ensembl: novel, ENST00000379376). However, the Vega program only defines RASSF2A as a coding
transcript (RASSF2B and RASSF2C are defined as unclassified non-coding transcripts). UTR regions are depicted by open boxes, exons by black boxes and CpG
islands by grey bars (as predicted by Ensembl). Ensembl (release 45) [20], Vega (release 24) [165], Prosite (release 20.9) [209].
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identity to that of NORE1.
2.2. Silencing of RASSF2 in cancer
Northern blot analysis revealed a single transcript (5.4 kb)
present in most tissues, with the signal being most intense in the
brain, peripheral blood, placenta, and lung [166]. Western blot
analysis demonstrated that the RASSF2 protein was frequently
down-regulated in human lung cancer cell lines [166].
RASSF2A CpG island hypermethylation corresponded with
loss of RASSF2A expression in colorectal cancer (CRC) cell
lines and treatment with the demethylating agent 5-aza-2-
deoxycytidine reactivated RASSF2A expression [164,167]. In
addition, single-strand conformation polymorphism analysis
and direct sequencing of RASSF2 in 10 CRC cell lines and 140
primary CRCs found only polymorphisms, making it highly
unlikely that inactivation of RASSF2 is caused by mutation
[167]. RASSF2 promoter methylation was observed in 21/30
(70%) of primary CRC tumours, and this methylation was
always tumour-specific (not detected in the matched patient’s
DNA from normal mucosa) [164] and occurred more frequently
than promoter methylation of any of the other RASSF genes
[167]. Methylation of the RASSF2A promoter appears to be an
early event in colorectal tumour development as RASSF2A
promoter hypermethylation has been reported in a high
proportion of colon adenomas, while DNA from matched
normal mucosa was unmethylated (interestingly, none of the
same colon adenomas demonstrated hypermethylation of the
RASSF1A promoter) [164,167]. Several studies have also
have reported a positive correlation of RASSF2 promoter
methylation with KRAS, BRAF or PIK3CA mutations in these
tumours [167–169], although some found these events to be
mutually exclusive (and there was also no association between
RASSF2A methylation status and RASSF1A or NORE1A
methylation status in these tumours).
RASSF2A promoter methylation has also been reported in
lung tumour cell lines and primary NSCLC tumours [166,170]
(although no positive association with KRAS or EGFR
mutations [170]) and is a frequent event in gastric cancer
[171] and nasopharyngeal carcinoma, in which it positively
correlates with lymph node metastasis [172]. Intriguingly,RASSF2 has been found to be up-regulated in radiation workers
(analysis of lymphocytes from three radiation-workers showed
RASSF2 was one of several induced genes that could be
associated with cell response to ionizing radiation) [173].
2.3. Tumour suppressor activities of RASSF2
RASSF2 binds directly to K-Ras in a GTP-dependent
manner via the RA domain, however, only weakly interacts
with H-Ras [166]. Two-hybrid screens have found that
RASSF2 also interacts/associates with NORE1, MST1 and
RASSF3 [158,164]. Over-expression of RASSF2 in A549
human lung cancer cells and RKO CRC cells caused an
inhibition of cell growth [166,167]. RASSF2-mediated growth
inhibition in 293-T cells was dramatically enhanced by the
presence of activated K-Ras, whereas H-Ras had little effect on
this activity [166]. The mechanistic basis of RASSF2-mediated
growth inhibition has been reported to be due to both apoptosis
(as demonstrated by caspase-3 activation, FACS analysis and
TUNEL assays) [166,167] and cell cycle arrest (RASSF2-
expressing cells showed a ∼20% decrease in the G2/M phase
of the cell cycle, suggesting the cells tended to arrest in the G0/
G1 phase) [166], depending on the cell line used. One study
found that introduction of exogenous RASSF2 induced
morphologic changes in CRC cell lines (DLD-1 and RKO)
associated with altered actin polymerization and suppression of
RhoA, which subsequently led to apoptosis [167]. It has been
proposed that inhibition of the RAS-signalling pathway
sensitizes cancer cells to suspension-dependent apoptosis
(anoikis) [174] and consistent with this, RASSF2-induced
apoptosis appeared to be caused by loss of adhesion followed
by anoikis [167].
Down-regulation of RASSF2 using siRNA has been
shown to enhance the ability of K-ras to transform rat
kidney cells, suggesting that tumour cells in which negative
regulators of K-ras (e.g., members of the RASSF family) are
silenced may have a growth advantage during transformation
[167]. The idea that silencing (methylation) of RASSF2 plays
a key role in KRAS-mediated transformation is supported by
reports that KRAS/BRAF mutations are found more frequently
in CRCs with RASSF2 methylation than in those without it
[167–169].
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3.1. Gene and protein structure of RASSF3
The RASSF3 gene, located at 12q14.1, is predicted to
produce 3 transcripts (RASSF3A, 3B and 3C), due to alternative
splicing of the exons (Fig. 6). The isoform described in the
literature is that of RASSF3A, which contains five exons and
encodes a 238-amino acid protein [175]. The last four exons
encode an RA and SARAH domain with a 44% identity (59%
homology) to the C-terminus of both RASSF1A and 1C
isoforms and 46% identity to the mouse Nore1 protein (Fig.
2). The N-terminal protein sequence of RASSF3A has no
similarity to RASSF1A or NORE1A but instead shares high
homology with the N-terminus of RASSF1C and NORE1B. The
nature of such a conserved sequence domain at the N-terminus of
these proteins is unknown, but it might be related to a specific
function of the shorter isoforms of this gene family. The
RASSF3B and 3C isoforms are shorter than RASSF3A, and do
not contain the RA or SARAH domains. The functional
significance of these isoforms is unknown and they have not
been described in the literature.
3.2. Silencing of RASSF3 in cancer
Northern blot analysis showed a 3.8-kb band in all normal
tissues (heart, brain, placenta, lung, liver, skeletal muscle,
pancreas, small intestine, colon, spleen, thymus, prostate, testis,
ovary and peripheral blood leukocytes) and human cancer cell
lines (including haematological, colo-rectal, lung, melanoma
and cervical cell lines) examined [175]. Although CpG islands
have been predicted in the RASSF3 locus (Fig. 6) RASSF3
promoter methylation has not been extensively studied, and
there has been no evidence for its methylation in either gliomas
(primary tumours or tumour cell lines) [97] or colorectal tumour
cell lines [164]. Although a two-hybrid screening of a human
lung cDNA library using an MST1 bait yielded multiple copies
of NORE1, RASSF1, RASSF2 and RASSF3 (thus showing
RASSF3 can interact with MST1) [158], no systematic
functional characterisation of RASSF3 has been performed
to-date.Fig. 6. Transcripts produced from the RASSF3 locus at chromosome 12q14. Three
1377-bp transcript composed of 5 exons and translating a 238-residue protein
ENST00000336061). RASSF3B is a 1099-bp transcript which splices from exon 2 to
neither a RA nor SARAH domain (Ensembl: Q86WH2-2, ENST00000283172). Sim
translates a 75-residue protein containing neither a RA nor SARAH domain (Vega
boxes, exons by black boxes and CpG islands by grey bars (as predicted by Ensemb
(release 24) [165], Prosite (release 20.9) [209].4. RASSF4
4.1. Gene and protein structure of RASSF4
RASSF4, also known as AD037, was identified using a
bioinformatics-based approach to detect novel RA domain-
containing proteins [176]. Alternative splicing of the RASSF4
gene at chromosome 10p11.21 is predicted to result in numerous
transcripts (Fig. 7 shows RASSF4A-F although additional
variants have been predicted). The only variant that has been
described in the literature is the RASSF4A isoform (and is just
referred to as RASSF4). RASSF4A is a 1337-bp transcript that
produces a protein of 321 amino acids that bears closest homo-
logy (∼60% identity) to RASSF2. RASSF4 lacks the cysteine-
rich domain present in RASSF1A and NORE1 and the putative
ATM phosphorylation site present before the RA domain in
RASSF1A. However, RASSF4 does contain the RA domain and
SARAHmotif present in the C-terminus of RASSF1A and other
family members (Fig. 2).
4.2. Silencing of RASSF4 in cancer
RASSF4 has a CpG island spanning the first exon and
RASSF4 expression was found to be lost in 12.5% (1/8) of
nasopharyngeal carcinoma cell lines/xenografts examined, with
bisulfite sequencing analysis revealing dense methylation in the
promoter region, and restoration of RASSF4 mRNA observed
after treatment with a demethylating agent [177]. RASSF4 is
broadly expressed in human tissues (heart, brain, placenta, lung,
liver, skeletal muscle and pancreas) but was found to be down-
regulated in some human tumour cell lines and primary tumours,
with down-regulated expression correlating with methylation of
the promoter (which could be reversed upon treatment with the
demethylating agent, 5-aza-2′-deoxycytidine) [176]. For exam-
ple, the CpG island of RASSF4 was frequently hypermethylated
in breast, lung, colorectal and kidney tumour cell lines and in
primary lung and breast tumours, with no methylation detected
in normal samples [176]. In contrast to the RASSF1A promoter
which is methylated in 70%–80% of primary SCLCs and 30–
34% of NSCLCs (suggesting that RASSF1Amethylation is more
important for the development of SCLC than NSCLC) [178], thetranscripts are predicted to be produced from the RASSF3 locus. RASSF3A is a
(Vega: RASSF3-001, OTTHUMT00000261784; Ensembl: RASF3_HUMAN,
exon 4 causing a shift in the reading frame and resulting in a protein containing
ilarly, RASSF3C contains only 2 exons and produces a transcript of 444 bp that
: RASSF2-002, OTTHUMT00000077829). UTR regions are depicted by open
l). Protein domains were predicted by Prosite. Ensembl (release 45) [20], Vega
Fig. 7. Transcripts produced from the RASSF4 locus at chromosome 10q11. Multiple transcripts are predicted from the RASSF4 locus. RASSF4A is a 2472-bp
transcript that translates a 321-amino acid protein (Vega: RASSF4-001, OTTHUMT00000047745; Ensembl: RASF4_HUMAN, ENST00000374411 [note: the
transcript predicted by Ensembl is only 2344 bp as it does not contain the 5′UTR]). RASSF4B and RASSF4C are very similar to RASSF4A, only differing in the N-
terminal exons, with the C-terminal RA and SARAH domains of the translated transcript being identical (Ensembl: Q9H2L5-2 and Q9H2L5-3, ENST00000334940
and ENST00000374417, respectively). RASSF4D (Ensembl: Q5T737_HUMAN, ENST00000374414), RASSF4E (Vega: RASSF-006, OTTHUMT00000047750) and
RASSF4F (Vega: RASSF4-008, OTTHUMT00000047752) transcripts are much shorter than the other isoforms due to premature truncation at exon 5, and as such the
translated proteins contain no RA or SARAH domains. There are an additional 9 transcripts predicted by the Vega program, however they are alternatively spliced
transcripts believed to contain intronic sequence relative to other coding variants or are unclassified non-coding transcripts, so for the sake of clarity these have not
been shown. UTR regions are depicted by open boxes, exons by black boxes and CpG islands by grey bars (as predicted by Ensembl). Protein domains were predicted
by Prosite. Ensembl (release 45) [20], Vega (release 24) [165], Prosite (release 20.9) [209].
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SCLCs (∼21% each) [176]. RASSF4 promoter methylation
was also found to only occur rarely in nasopharyngeal carcinoma
(1/20 of the samples examined) [177], and in glioma cell lines
but not in primary tumours [97]. The coding sequence of
RASSF4 was examined for potential inactivating mutations, but
none were detected [176].
4.3. Tumour suppressor activities of RASSF4
RASSF4 binds directly to activated, but not wildtype, K-Ras
in a GTP-dependent manner via the RA domain [176]. Over-
expression of RASSF4 induced cell death in 293-T cells, which
was enhanced by the presence of activated K-Ras [176].
Examination of the mechanism by which RASSF4 promotes
cell death showed that RASSF4 activated caspases, suggesting
that the cell death was apoptotic (RASSF4 was also found to
bind proapoptotic MST1 when the two proteins were exogen-
ously expressed) [176]. An established method of activating Ras
effectors is to add a C-terminal CAAX membrane localization
motif (C, cystein; A, aliphatic amino acid; X, serine or
methionine) [179], and RASSF4-mediated apoptosis (caspase
activation) in MCF-7 cells was further enhanced by the addition
of a Ras-CAAX motif to its C-terminus [176]. Over-expression
of RASSF4 also inhibited cell growth (colony formation) in
MCF-7 cells and A549 lung cancer cells (but not H1299 lung
cancer cells) and the effect again enhanced by the addition of a
Ras-CAAX motif to the C-terminus of RASSF4 [176].5. NORE1
5.1. Gene and protein structure of NORE1
The closest homolog of RASSF1 is novel Ras effector 1
(NORE1), also known as RASSF5. Indeed, mouse Nore1 was
actually discovered before human RASSF1; shortly after the
identification ofNore1 in 1998 [15], Damman and co-workers in
2000 described a gene located in the short arm of chromosome 3
(one of the most frequently encountered cytogenetic alterations
in lung cancer and several other epithelial neoplasms), whose
protein was ∼50% identical to Nore1 in overall sequence and
contained an RA domain in its C-terminal region, hence was
named “Ras association domain family 1” (RASSF1) [13].
NORE1 is located on chromosome 1q32.1, and several
transcripts have been predicted to be produced from this locus
(see Fig. 8). NORE1Aα produces a 418-amino acid protein,
NORE1A, containing an RA, SARAH and DAG-binding
domain and NORE1B produces a 265-amino acid protein,
NORE1B, containing the RA and SARAH domains but not the
DAG-binding domain (Fig. 2) [175,180]. Similar to the RASSF1
gene, the two major transcripts, RASSF1A and RASSF1C,
encode proteins that exhibit architecture homologous to the
NORE1A andNORE1B isoforms, in that they share common RA
and SARAH domains in the C-terminus, but have distinct N-
termini. Like RASSF1A, NORE1A has a central DAG binding
domain N-terminal to the RA domain, whereas NORE1B, like
RASSF1C, has a short N-terminal segment containing no
Fig. 8. Transcripts produced from the RASSF5 locus at chromosome 1q32. Several transcripts are produced from the RASSF5 locus. NORE1Aα is a 2048-bp transcript
that translates a 418-amino acid protein (Vega: RASSF5-001, OTTHUMT00000088469; Ensembl: RASF5_HUMAN, ENST00000367118) and NORE1B is a 3496-bp
transcript that translates a 265-amino acid protein (Vega: RASSF5-003, OTTHUMT00000088471; Ensembl: Q8WWW0-2, ENST00000304534). additional 2
transcripts are predicted, namely NORE1Aβ (Vega: RASSF5-002, OTTHUMT00000088470; Ensembl: Q8WWW0-3, ENST00000355294), which splices from exon 4
to exon 6 causing a shift in the reading frame that results in premature termination and NORE1Aγ (Vega: RASSF5-004, OTTHUMT00000088472), which has a C-
terminal truncation of exon 6, and; translation of these transcripts produces proteins lacking the C-terminal SARAH domain. Additional transcripts have been predicted
by the Vega program but as they are non-coding they have not been shown (Vega: RASSF5-005 and -006, OTTHUMT00000088473 and OTTHUMT00000088474,
respectively). UTR regions are depicted by open boxes, exons by black boxes and CpG islands by grey bars (as predicted by Ensembl). Protein domains were predicted
by Prosite. Ensembl (release 45) [20], Vega (release 24) [165], Prosite (release 20.9) [209].
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duced from this locus, namely NORE1Aβ and NORE1Aγ, how-
ever, the proteins produced from these transcripts do not encode
the SARAH domain and there are no reports of their functional
characterisation in the literature.
NORE1 is the human homologue of the mouse Ras effector,
Nore1 [15]. Nore1 was discovered in a two-hybrid screen
using H-RasG12V as bait; the initial isolate, obtained from a
murine T-cell cDNA library, was a partial cDNA encoding the
Nore1B isoform, however, the isoform first characterized was
a full-length murine Nore1A isolated from brain cDNA [15]. In
addition to binding activated Ras, NORE1B (identified as
RAPL) was independently isolated by virtue of its ability to bind
activated Rap1 in stimulated T cells and to regulate lymphocyte
adhesion by associating with the integrin LFA-1 and relocating
at the immunological synapse (see Section 5.4). The RA domain
of Nore1 binds to Ras-GTP (active Ras) with strong preference
over Ras-GDP (inactive Ras) in vitro and endogenous Nore1
binds endogenous Ras in vivo in response to EGF or serum-
stimulation [15]. Subsequent yeast two-hybrid studies showed
that Nore1 associates with other Ras-like GTPases (including
Rap1, Rap2, RRas, RRas2/TC21, and RRas3/MRas) with an
affinity comparable to that seen for H- and K-Ras [156]. In
addition, it was shown that the hetero-dimerisation of NORE1
with RASSF1A was crucial for the ability of RASSF1A to
associate with Ras-like GTPases [156].
5.2. Silencing of NORE1 in cancer
Both NORE1A and NORE1B have separate CpG islands
spanning their first exons (see Fig. 8). NORE1A is widely
expressed in normal tissues, however, several cancer cell lines
(promyelocytic leukaemia HL-60, lymphoblastic leukemia
MOLT-4, Burkitt’s lymphoma Raji, lung carcinoma A549 and
melanoma G361 cells) expressed very low levels of NORE1A
transcript (colorectal adenocarcinoma SW80, myelogenousleukemia K562 and HeLa cells showed transcript levels
comparable to those in normal tissues) [175,181]. Similarly,
NORE1B also has a wide tissue distribution with absent or
down-regulated expression in some cancer cell lines (HeLa,
A549, and G361 cells) [175,181]. Aoyama and co-workers
surveyed a variety of human tumour cell lines by PCR and also
observed that a majority of those examined exhibited very low
levels of NORE1A mRNA, with NORE1B expression being
more variable [182]. Western blot using an antibody that
detected both isoforms of NORE1 found the majority of human
lung tumour cell lines examined (11/14) had lost NORE1 ex-
pression and expression was also severely reduced or completely
absent in the majority of the epithelial-derived adenocarcinomas
and SCLCs examined (4/5 of each subtype) [181]. Significantly
suppressed NORE1A and RASSF1A mRNA levels have been
detected in pheochromocytoma primary tumours compared with
normal adrenal medulla, however, methylation of the NORE1A
promoter was not observed [99]. Other studies have also found
no evidence of methylation of either NORE1A or NORE1B CpG
islands in the various tumours examined, including melanomas,
nasopharyngeal carcinomas, cervical carcinomas, lung tumours
and thyroid tumours and hepatitic livers (those showing chronic
hepatitic/cirrhosis, hepatocellular nodules and HCC) [102,175,
177,183,184] and deletions or mutations of chromosome
1q32.1–2 in the vicinity of the NORE1 gene is not common
in human tumours, except for in renal collecting duct carcinoma
(a rare malignant neoplasm of distal nephron origin) [185]. In
addition, a family with clear cell renal cell carcinomas (RCC)
was found to harbour a translocation between the NORE1 gene
on chromosome 1q32.1 and the LSAMP gene on chromosome
3q13.3 that results in haploinactivation of the NORE1 gene
[186].
However, there have been reports of evidence of epigenetic
inactivation ofNORE1 by promoter methylation in tumours. For
example, Vos and co-workers found methylation of the NORE1
promoter in some lung cancer cell lines (A549 and H345 cells)
75L. van der Weyden, D.J. Adams / Biochimica et Biophysica Acta 1776 (2007) 58–85and treatment with the demethylating agent, 5-aza-2′-deoxycy-
tidine (but not the deacetylating agent, trichostatin A), caused an
increase in NORE1 expression, confirming that promoter
silencing by methylation rather than acetylation or gene deletion
is the likely mechanism behind the down-regulation of NORE1
expression in lung tumour cells [181]. Methylation of the
NORE1A promoter has been reported in various tumour types,
including lung, breast, and kidney tumour cell lines and primary
tumours (but not in normal tissues) [180,181,186,187], and
NORE1A expression in the tumour cell lines was reactivated
after treatment with a demethylating agent [180]. Interestingly,
in lung cancer this hypermethylation appeared to be histological
type specific as 24% (6/25) of primary NSCLC underwent
NORE1Amethylation, but methylation in SCLCwas a rare event
(0/22) [180] and epigenetic alteration of NORE1Awas confined
to NSCLC tumours with a wild-type K-ras (15/17 of the tumours
with NORE1 hypermethylation did not harbour a K-ras muta-
tion) [112]. Furthermore, aberrant methylation of NORE1A and
SOCS3 promoters has been found to be observed only in a
subclass of HCCwith poor survival, suggesting that inactivation
of these 2 genes might be involved in HCC progression [103]. In
contrast,NORE1B promoter was found to be unmethylated in all
lung and breast cell lines and primary tumours examined [180]
and gliomas (primary tumours or tumour cell lines) [97].
However, methylation of the NORE1B promoter has recently
reported in 62% of hepatocellular carcinomas and hepatocarci-
noma cell lines examined (compared to only 4% showing
NORE1A promoter methylation) [188].
Ras mutations and NORE1A down-regulation have been
reported to be mutually exclusive events in follicular thyroid
tumours [184], where as others have found no correlation
between NORE1 expression and the presence or absence of a
Ras mutation (in melanomas, cervical carcinomas, and lung
tumours) [181]. Interestingly, one study found although the
NORE1A mRNA levels of the majority of the follicular thyroid
tumours examined were similar to those in the normal controls,
the cases harbouring a PAX8-PPAR11 translocation (n=6)
exhibited dramatically reduced NORE1A expression [184].
Another study found NORE1B and RASSF1A to be epigeneti-
cally down-regulated alone in at least 62%, or in combination in
97% of the HCCs studied, in contrast to every third fibrotic or
cirrhotic liver only exhibiting silencing of one or both genes,
suggesting it may be a critical event allowing HCCs to subverse
growth control in the presence of an unaltered Ras (which is
rarely mutated in HCCs) [188]. In contrast, no correlation
between NORE1A and RASSF1A methylation status was found
in NSCLC [180] or renal cell carcinoma and Wilms’ tumour
[187].
5.3. Tumour suppressor activities of NORE1
5.3.1. Growth suppression
Re-introduction of NORE1A or NORE1B suppressed the
growth of the NORE1-deficient A549 lung cancer cell line and
the G361 melanoma cell line (which have disrupted Ras
signaling due to a Ras activating mutation or constitutively
active B-Raf kinase, respectively) [181,182]. However, whentransfected into other NORE1-deficient cell lines with similar
disruptions to Ras signalling (the NCI-H460 lung cancer and
M14 melanoma cell line), there was no effect on colony
formation [182]. Stable expression of NORE1A also impairs the
growth of A549 human lung cells and PC12 rat pheochromo-
cytoma cells in soft agar (inhibition of anchorage-independent
growth) [99,182]. However, the mechanism behind NORE1-
induced growth suppression is not clear. Vos and co-workers
found that NORE1-mediated growth suppression occurred in a
Ras-dependent manner (NORE1-mediated growth inhibition in
293T cells was increased in the presence of activated H-Ras but
decreased in the presence of the H-Ras dominant negative
mutant Q61L/C186S), primarily by the induction of apoptosis
(the growth suppression was blocked by co-transfection with the
anti-apoptotic oncogene, Bcl-2, and caspase activity was
detected) [181]. However, another study found that NORE1A-
induced growth suppression occurred through a mechanism
independent of its ability to bind to activated Ras-like GTPases
and the MST1/2 kinases (as determined by transient transfection
of a series of deletion mutants of NORE1 into A549 cells),
primarily by inducing cell cycle delay rather than apoptosis
(expression of NORE1A causes a significant decrease in the
number of cells in the S phase and a reciprocal increase of the
fraction in the G1 phase, similar to the inhibition of cell cycle
progression through G1 reported for RASSF1A [43]) [182]. It
was recently proposed that cytoskeletal localization is required
for the growth-suppressive effects of NORE1A and that this
occurs through the ERK signalling pathway [189].
5.3.2. Apoptosis
The ability of NORE1 on its own to induce apoptosis
remains unclear. Studies have found that transient expression of
NORE1 induced apoptosis in 293T cells [181] and PC12 rat
pheochromocytoma cells [99], whilst others found that NORE
over-expression does not promote apoptosis in mammalian cells
[21,182]. NORE1 has been shown to bind the pro-apoptotic
protein kinase MST1 (via the SARAH domain) [21,190].
Whereas over-expression of MST1 induced apoptosis in
NIH3T3 cells, and co-expression with NORE1 had small effect
on increasing apoptosis, the addition of a CAAX motif to
NORE1 to induce membrane targeting enabled NORE1 alone to
induce apoptosis, and NORE1 together with MST1 had a
greater pro-apoptotic effect than either protein alone (and this
cell death was inhibited by the caspase inhibitor, z-VAD-fmk)
[21]. Endogenous NORE1 and MST1 occur in a constitutive
complex in vivo that associates with endogenous Ras after
serum stimulation [21]. Over-expression of constitutively active
Ki-RasG12V promotes apoptosis in a variety of cell lines,
however, this is suppressed by over-expression of the C-
terminal non-catalytic portion of MST1 (containing auto-
inhibitory, dimerisation, and NORE1 binding domains) or by
the portion of NORE1 that binds MST1 (H-RasGV12, E37G-
mediated apoptosis was also suppressed) [21]. Thus the
NORE1–MST1 complex is a novel Ras effector unit that
mediates the apoptotic effect of Ras. It was subsequently
proposed that NORE1/RASSF1 proteins, in addition to their
role in maintaining the low activity of MST1 in vivo, direct
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endogenous substrates [158].
Thus, the weight of evidence indicates that the NORE1
proteins, like the RASSF1 proteins, are inhibitory to cell
growth, and the A isoforms of both RASSF1 and NORE1 are
likely to function as tumour suppressors that undergo inactiva-
tion primarily by epigenetic mechanisms.
5.4. NORE1B in the immune system
In addition to its role as a tumour suppressor gene, NORE1B
has also been shown to play an important role in the immune
system [reviewed in 191]. NORE1Bwas first characterised in its
ability to mediate the Rap1-induced polarized accumulation and
increased affinity of LFA-1 in response to T-cell receptor (TCR)
activation, and as a result was named RAPL (‘regulator of
adhesion and polarization enriched in lymphocytes’) [192]. Rapl
knockout mice were found to be notably impaired in various
aspects of their immune response (such as defective adhesion
and migration of lymphocytes and dendritic cells) [193]. RAPL
has been shown to localise to the microtubules (and activated
Rap1 can induce their dissociation from microtubules) [194].
Recently, a yeast two-hybrid screen using an activated RAPL
mutant protein as bait identified the proapoptotic kinase MST1
as a binding partner, demonstrating a previously unknown
function for MST1 of relaying the Rap1-RAPL signal to induce
cell polarity and adhesion of lymphocytes [195]. Endogenous
RAPL has also been suggested to modulates Ras signalling
outputs triggered by TCR stimulation via recruiting active Ras to
the plasma membrane and by contributing to the localization of
Carma1 (an essential lipid raft-associated regulator of TCR-
induced NF-κB activation) [196].
6. RASSF6
6.1. Gene and protein structure of RASSF6
The RASSF6 gene comprises of 13 exons and is localized at
chromosome 4q13.3. As shown in Fig. 9, three transcripts are
predicted to be produced from the RASSF6 locus, namelyFig. 9. Transcripts produced from the RASSF6 locus at chromosome 4q13. Three tra
that translates a 337-amino acid protein (Vega: RASSF6-001, OTTHUMT0000025227
predicted to be slightly smaller at 5123 bp due to a shorter 3′UTR sequence). RASSF6
002, OTTHUMT00000252279; Ensembl: RASF6_HUMAN, ENST00000342081; th
longer 3′UTR sequence). RASSF6C is 1360 bp and translates a 325-amino acid
ENST00000335049) that differs from RASSF6A and B only at the N-terminus due
depicted by open boxes, and exons by black boxes (no CpG islands were identifiedRASSF6A, RASSF6B, and RASSF6C (although the latter
isoform has not been described in the literature). RASSF6B
has an additional 32 amino acids in the N-terminal region
compared to RASSF6A, and RASSF6C has a different N-
terminus from both RASSF6A and 6B. However, all isoforms
possess the conserved RA and SARAH domains that are
characteristic of the RASSF family (Fig. 2). The RA domain of
RASSF6 is more similar to those of RASSF2 and RASSF4
(∼50% identity) than RASSF1A (∼30% identity). The
homology of RASSF6 with other members is lower in the
SARAH domain (which is ∼40% identical to those of RASSF2
and RASSF4, and ∼20% identical to those of RASSF1A and
NORE1) [197]. Although it possesses an RA domain, similar to
the RASSF1 situation [50,156] it is a somewhat controversial
issue as to whether RASSF6 directly or indirectly binds Ras
proteins; one study reported that RASSF6 interacts directly with
K-Ras in a GTP-dependent manner with an affinity comparable
to that of other known Ras effectors [198] yet another study
reported it does not bind K-Ras, H-Ras, N-Ras, M-Ras, or TC21
under the conditions that NORE1 binds these Ras proteins
[197].
6.2. Silencing of RASSF6 in cancer
RASSF6 transcript was detected in several cancer cell lines
including HeLa, MCF-7, U373, A549, and HepG2 cells [197]
but reduced levels were found in 30–60% of primary tumour
tissues of the breast, colon, kidney, liver, pancreas, stomach and
thyroid gland [198]. Interestingly, only 1/7 of the tumour cell
lines examined demonstrated partial promoter methylation, and
given that the 4q21.21 region has been reported to suffer
deletions during tumour development [199], it has been
proposed that the loss of RASSF6 expression in primary tumours
may involve gene deletions as well as epigenetic mechanisms of
silencing [198]. Indeed, whilst some bioinformatics programs
predict the positioning of CpG islands within the RASSF6
promoter (CpG Island Searcher [200]), others do not (Ensembl
[20]), so further studies are needed to determine whether methy-
lation of the RASSF6 promoter does occur. One study also found
that some tumour samples appeared to exhibit elevated levels ofnscripts are produced from the RASSF6 locus. RASSF6A is a 5872-bp transcript
8; Ensembl: Q6ZTQ3-2, ENST00000307439; the Ensembl transcript is actually
B is a 4331-bp transcript that translates a 369-amino acid protein (Vega: RASSF6-
e Ensembl transcript is actually predicted to be slightly larger at 4902 bp due to a
protein (Vega: RASSF6-003, OTTHUMT00000252280; Ensembl: Q6ZTQ3-3,
to use of an alternative exon 2 and splicing around exon 3. UTR regions are
; as predicted by Ensembl). Ensembl (release 45) [20], Vega (release 24) [165].
Fig. 10. Transcripts produced from theRASSF7 locus at chromosome 11p15. Three
transcripts are produced from the RASSF7 locus due to use of different N-terminal
and C-terminal exons. RASSF7A (Vega: RASSF7-003, OTTHUMT00000254972;
Ensembl: RASF7_HUMAN, ENST00000344375) is a 1902-bp transcript that
initiates transcription from the ATG present in exon 2, utilises different C-terminal
exons from the other RASSF7 transcripts and corresponds to the HRC1 type I
transcript identified by Weitzel and colleagues [203]. RASSF7B (Vega: RASSF7-
002, OTTHUMT00000254971) uses an alternative first exon to RASSF7A to
generate a 1745-bp transcript that translates a 377-amino acid protein. RASSF7C
(Vega: RASSF7-001,OTTHUMT00000254970) differs from RASSF7B only in the
N-terminal exon and is a 1731-bp transcript that translates a 366-amino acid protein.
UTR regions are depicted by open boxes, exons by black boxes and CpG islands by
grey bars (as predicted by Ensembl). Each of these proteins contain an N-terminal
RA domain (as predicted by Prosite). Ensembl (release 45) [20], Vega (release 24)
[165], Prosite (release 20.9) [209].
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this remains as yet unknown [198].
6.3. Tumour suppressor activities of RASSF6
Consistent with a role as a tumour suppressor, over-
expression of RASSF6 inhibited the survival of specific tumour
cell lines; both RASSF1A and RASSF6 inhibited the growth of
MCF-7 human breast tumour cells, RASSF6 was significantly
less effective than RASSF1A at inhibiting the growth and
survival of A549 human lung tumour cells, and neither
RASSF1A nor RASSF6 inhibited the growth of the H1299
human lung tumour cell line [198]. siRNA knockdown of
RASSF6 in the H1792 NSCLC cell line enhanced their ability to
grow in soft agar, relative to control cells [198]. Similar to
RASSF1A, over-expression of RASSF6 induced apoptosis in
both the MCF-7 cell line [198] and the HeLa cervical cancer cell
line [197]. RASSF6 was found to activate Bax, induce cyto-
chrome c release and trigger both caspase-dependent and
caspase-independent pathways of apoptosis [197]. Similar to
RASSF1A, RASSF6 could co-immunoprecipitate with MAP-1
and this binding was enhanced by the presence of activated K-
Ras (suggesting a potential mechanism by which Ras may
activate the pro-apoptotic effects of RASSF6) [198]. RASSF6
knockdown in HeLa cells also partially blocked TNFα-induced
cell death (similar to RASSF1A, for which a role in death
receptor-mediated apoptosis has been implicated) [197].
6.4. RASSF6 in the immune system
A biological property of RASSF6 that is unique from other
members of the RASSF family is its potential to play a role in
dictating the degree of inflammatory response to the respiratory
syncytial virus (RSV). RASSF6 was discovered within a 250-kb
region on chromosome 4q21.21 associated with RSV-induced
acute bronchiolitis [201]. One of the major effects of RSV
infection is activation of the eukaryotic nuclear factor kb (NF-
κB) pathway and this plays a critical role in both promoting
inflammation and supporting viral replication by suppressing
apoptosis [202]. Recently, RASSF6 expression has been shown
to inhibit the basal levels of NF-κB activity in a lung epithelial
cell line and this appears to be a specific effect as RASSF2 (the
closest family member) exhibited only a modest effect on NF-
κB activation [198]. Thus it is possible that defects in RASSF6
may facilitate viral NFkB activation by RSV, and enhance the
infection. It is tempting to speculate a potential role of RASSF6
in inflammation in cancer.
7. RASSF7
7.1. Gene and protein structure of RASSF7
First identified in a cluster of three genes within 32 kb
upstream of H-RAS1 on chromosome 11p15, RASSF7 was
originally termed HRAS1 cluster 1 (HRC1) [203] (and is also
known as C11ORF13). Due to alternative splicing, 3 transcripts
have been predicted to be produced from this locus, RASSF7A,RASSF7B and RASSF7C (see Fig. 10). These isoforms differ
primarily in the C-terminus (although RASSF7A has a truncated
N-terminus in comparison to the other isoforms), and each
possess an N-terminal RA domain (see Fig. 2) although it is not
known whether they directly bind Ras, as the presence of the RA
domain does not necessarily signify RAS binding affinity of a
protein [204,205]. They also do not possess a SARAH domain,
in contrast to RASSF1-6 family members. Thus not surprisingly,
RASSF7 shows greatest homology to RASSF8 (e.g. RASSF7A
shows 42% similarity to RASSF8Ayet only 23% to RASSF1A),
which also possesses an N-terminal RA domain and no SARAH
domain (see Section 8).
7.2. The role of RASSF7 in tumourigenesis
Although CpG islands at the RASSF7 locus have been both
predicted (see Fig. 10) and experimentally observed [203], it
has not yet been reported whether hypermethylation of the
RASSF7 promoter occurs in tumours, and indeed whether any of
the RASSF7 isoforms play a role in tumourigenesis.
8. RASSF8
8.1. Gene and protein structure of RASSF8
Similar to RASSF7, which is located close to the HRAS1
gene, RASSF8 is located close to the KRAS2 gene (70.8 kb
from KRAS2 on chromosome 12p11). RASSF8 is also known
as HoJ-1 and C12ORF2. Although Favella and colleagues
identified several 5′ UTR variants originating from alternative
splicing of exons 1–3 [206], Ensembl [20] and Vega [165]
bioinformatics programs primarily predict transcripts which
differ due to premature truncation at the C-terminus (exons
Fig. 11. Transcripts produced from the RASSF8 locus at chromosome 12p12. Multiple transcripts are predicted to be produced from the RASSF8 locus. RASSF8A
(Ensembl: RASF8_HUMAN, ENST00000381352) and RASSF8B (Vega: RASSF8-001, OTTHUMT00000260394; Ensembl: Q8NHQ8-2, ENST00000282884) are
very similar, differing only in their C-terminal exon, and both encode proteins containing an N-terminal RA domain. RASSF8C-E transcripts (Vega: RASSF8-003, -004
and -005, OTTHUMT00000260396, OTTHUMT00000260397, and OTTHUMT00000260398, respectively) prematurely terminate at the 5′ end of exon 4 and
translate a 91-, 107- and 134-amino acid protein, respectively, that almost consists entirely of the RA domain. RASSF8F (Vega: RASSF8-002,
OTTHUMT00000260395) uses an alternative third exon however, as most of this is part of the 5′UTR, the transcript generates a 24-amino acid protein with no
recognisable domains. Similarly, RASSF8G (Vega: RASSF8-006, OTTHUMT00000260399) only translates a 40-amino acid protein containing no recognisable
domains. UTR regions are depicted by open boxes, exons by black boxes and CpG islands by grey bars (as predicted by Ensembl). Protein domains were predicted by
Prosite. Ensembl (release 45) [20], Vega (Release 24) [165], Prosite (Release 20.9) [209].
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from this locus (though most remain to be experimentally
verified). RASSF8A and RASSF8B encode 419 and 392
amino acid proteins, respectively which differ only in their C-
terminus (due to the use of a different C-terminal exon).
Similar to RASSF7A–C, these proteins contain an N-terminal
RA domain (see Fig. 2), although it is not known whether
they directly bind Ras. RASSF8C–E isoforms are truncated
forms of RASSF8A and 8B (due to premature truncation of
the transcript in exon 4) and consist primarily of just the RA
domain. The RASSF8F and RASSF8G isoforms utilise
different exons from RASSF8A and 8B and produce very
short proteins of only 24 and 40 amino acids, respectively,
which contain no identifiable functional domains, and thus are
of unknown significance. Similar to RASSF7A–C, none of
the RASSF8 isoforms possess a SARAH domain.
8.2. The role of RASSF8 in tumourigenesis
Although CpG islands have been predicted for the RASSF8
locus (see Fig. 11), it is not known whether selective
methylation of the RASSF8 promoter is found in tumours.
However, it was recently reported that common polymorphisms
in RASSF8 are not associated with lung adenocarcinoma risk
[207]. Favella and colleagues found a decrease in RASSF8A
transcript abundance in lung adenocarcinoma as compared to
normal lung tissue, raising the possibility that this gene plays a
role in the negative control of tumour development [206]. Inagreement with this, anchorage-independent growth in soft
agar was significantly reduced in RASSF8A-transfected A549
lung cancer cells compared to cells transfected with empty
vector [206]. RASSF8 has also been implicated in a complex
type of synpolydactyly by the reciprocal chromosomal
translocation t(12;22)(p11.2;q13.3), which involves genes
RASSF8 and FBLN1 [208].
9. Concluding remarks
As described in this review, the RASSF genes have been
shown to have a diverse range of functions including cell cycle
regulation and the regulation of microtubule stability in
addition to roles in the control of apoptosis and proliferation.
This review describes how silencing of RASSF genes, and
deregulation of their diverse functions, are likely to be of
critical importance in mediating tumour suppression. The exact
contribution of each family member to tumour suppression, in
each cell type and tissue, is yet to be fully elucidated and the
prognostic and diagnostic utility of these genes, compared to
other available biomarkers, will require further large systema-
tic clinical studies prior to clinical laboratory tests for these
genes becoming commonplace. However, should the newly
developed chemotherapeutic methylation inhibitors, such as
zebularine and MG98, prove their efficacy in the clinic then it
is likely that tests for inactivation of RASSF genes, particularly
RASSF1A, will gain importance as a means for assessing
therapeutic response.
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members has been derived from detailed in vitro analyses. In
the near future the generation of knockout models of all RASSF
genes is likely to contribute greatly to our knowledge and
understanding of how these genes participate in tumour
suppression and will also help us understand the complex
interplay between mutations in RASSF genes and other genes in
the genome of cancer cells during the genesis of a tumour. In
conclusion we still have much to learn about the function of the
RASSF gene family members but hopefully we will be able to
exploit their secrets as a means for better treating and diag-
nosing patients in the cancer clinic.
RASSF1A has been reported to control mitotic progressing
by binding and inhibiting Cdc20 [133] (see section 1.8.2),
however, a recent study could find no such interaction between
RASSF1A and Cdc20 [210].
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